[go: up one dir, main page]

WO1997028181A3 - Post-labeling stabilization of radiolabeled proteins and peptides - Google Patents

Post-labeling stabilization of radiolabeled proteins and peptides Download PDF

Info

Publication number
WO1997028181A3
WO1997028181A3 PCT/US1997/001695 US9701695W WO9728181A3 WO 1997028181 A3 WO1997028181 A3 WO 1997028181A3 US 9701695 W US9701695 W US 9701695W WO 9728181 A3 WO9728181 A3 WO 9728181A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
labeling
stabilization
post
radiolabeled proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/001695
Other languages
French (fr)
Other versions
WO1997028181A2 (en
WO1997028181A9 (en
Inventor
Paul O Zamora
Michael J Marek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhomed Inc
Original Assignee
Rhomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhomed Inc filed Critical Rhomed Inc
Priority to CA002279349A priority Critical patent/CA2279349C/en
Priority to AU25264/97A priority patent/AU2526497A/en
Publication of WO1997028181A2 publication Critical patent/WO1997028181A2/en
Publication of WO1997028181A3 publication Critical patent/WO1997028181A3/en
Publication of WO1997028181A9 publication Critical patent/WO1997028181A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.
PCT/US1997/001695 1996-02-02 1997-02-03 Post-labeling stabilization of radiolabeled proteins and peptides Ceased WO1997028181A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002279349A CA2279349C (en) 1996-02-02 1997-02-03 Ascorbate-stabilized radiopharmaceutical method and composition
AU25264/97A AU2526497A (en) 1996-02-02 1997-02-03 Post-labeling stabilization of radiolabeled proteins and peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1102796P 1996-02-02 1996-02-02
US60/011,027 1996-02-02

Publications (3)

Publication Number Publication Date
WO1997028181A2 WO1997028181A2 (en) 1997-08-07
WO1997028181A3 true WO1997028181A3 (en) 1997-10-09
WO1997028181A9 WO1997028181A9 (en) 1998-03-05

Family

ID=21748542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/001695 Ceased WO1997028181A2 (en) 1996-02-02 1997-02-03 Post-labeling stabilization of radiolabeled proteins and peptides

Country Status (3)

Country Link
AU (1) AU2526497A (en)
CA (1) CA2279349C (en)
WO (1) WO1997028181A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
JP2004529884A (en) * 2001-02-26 2004-09-30 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Ascorbic acid analogs for metal radiopharmaceuticals
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101495094B (en) 2006-08-09 2011-11-09 精达制药公司 Osmotic Delivery System and Piston Assembly
PT2157967E (en) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
HUE071169T2 (en) 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilized, radiolabeled anti-CD45 immunoglobulin preparations
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401646A (en) * 1981-05-08 1983-08-30 University Patents Inc. Method and apparatus for purifying materials radiolabeled with technetium-99m
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5308603A (en) * 1990-03-27 1994-05-03 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5384113A (en) * 1991-08-29 1995-01-24 Mallinckrodt Medical, Inc. Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
US5405597A (en) * 1991-09-10 1995-04-11 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401646A (en) * 1981-05-08 1983-08-30 University Patents Inc. Method and apparatus for purifying materials radiolabeled with technetium-99m
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5308603A (en) * 1990-03-27 1994-05-03 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5384113A (en) * 1991-08-29 1995-01-24 Mallinckrodt Medical, Inc. Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
US5405597A (en) * 1991-09-10 1995-04-11 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Also Published As

Publication number Publication date
CA2279349C (en) 2007-09-25
WO1997028181A2 (en) 1997-08-07
CA2279349A1 (en) 1997-08-07
AU2526497A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
WO1997028181A3 (en) Post-labeling stabilization of radiolabeled proteins and peptides
UA26855C2 (en) Pharmaceutical composition regulating hematopoiesis
ES2130428T3 (en) INSULIN CRYSTALS ASP-B28.
AU694229B2 (en) A pharmaceutical preparation comprising glucagon
EP0950665A4 (en) Modified physiologically active proteins and medicinal compositions containing the same
EP0731712A4 (en) PHYSIOLOGICAL STABILIZED BUTTERIC ACID PREPARATIONS, AND BUTTERIC ACIDS AND DERIVATIVES AS ANTINEOPLASTIC ACTIVE SUBSTANCE
FR2784294B1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE WALL EXTRACT, AT LEAST ONE SCUTELLAR EXTRACT AND AT LEAST ONE SALICYLIC ACID DERIVATIVE
DE19775083I2 (en) 7-piperazinyl or 7-morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents
IL125800A0 (en) Thermally stabilized contrast agent
HUP0100284A2 (en) Activated protein c formulations
EP0232849A3 (en) Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
HUP0003840A2 (en) Controlled released medical formulation
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
ZA975755B (en) Useful formulations of acid addition salt drugs.
ATE203903T1 (en) DELTA-AMINOLEVULIC ACID CONTAINING MEDICINAL PRODUCT
MD980129A (en) Antiherpetic remedy
HUP9802437A3 (en) 5-pyrazolylbenzoic acid derivatives, herbicidal, desiccant and defoliant compositions containing these compounds as active ingredients, preparation and use of the latest
AU5740799A (en) Use of polyaspartic acid in hair-treatment preparations
Glowski Living goddess as incarnate image: The Kumari Cult of Nepal
IL83411A0 (en) Benzohydroxamic acid derivatives,their preparation and their use as herbicides
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
UA30011A (en) The method of prophylaxis of acute stress gastrointestinal tract lesions after the cavitary surgery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WD Withdrawal of designations after international publication

Free format text: US

WD Withdrawal of designations after international publication

Free format text: US

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97527884

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2279349

Country of ref document: CA

Ref country code: CA

Ref document number: 2279349

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase